This article is more than 5 years old. Information may no longer be current.
Oramed enrolls first patient in study of oral insulin capsule for NASH
Click Here to Manage Email Alerts
Oramed Pharmaceuticals enrolled the first patient in an exploratory clinical study of ORMD-0801, an oral insulin capsule designed for the treatment of nonalcoholic steatohepatitis, according to a press release.
“Prevalence of NASH is accelerating rapidly and correlates directly with the rising incidence of type 2 diabetes,” Nadav Kidron, CEO of Oramed, said in the release. “As we continue our focus on the development of our oral insulin for the treatment of diabetes, we are excited about its potential in this greatly needed NASH indication.”
The study was recently approved by Israel’s Ministry of Health and will include 3 months of treatment. Researchers will assess the efficacy of ORMD-08081 in reducing liver fat content, inflammation and fibrosis in patients with NASH.
Previous studies have shown a potential for ORMD-08081 to reduce inflammation of the liver.
Reference: www.oramed.com